Nascent Biotech, Inc. (OTCMKTS:NBIO – Get Free Report) crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.09 and traded as low as $0.07. Nascent Biotech shares last traded at $0.07, with a volume of 103,490 shares changing hands.
Nascent Biotech Stock Up 21.4 %
The business’s fifty day moving average is $0.09 and its two-hundred day moving average is $0.12.
About Nascent Biotech
Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.
See Also
- Five stocks we like better than Nascent Biotech
- Energy and Oil Stocks Explained
- Celebrate July 4th with These Red, White, & Blue Chip Stocks
- The How and Why of Investing in Gold Stocks
- AbbVie Stock: A Perfect Dip for Investors to Buy
- EV Stocks and How to Profit from Them
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
Receive News & Ratings for Nascent Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nascent Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
